Myr Gmbh News Today : Breaking News, Live Updates & Top Stories | Vimarsana
Stay updated with breaking news from Myr gmbh. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Top News In Myr Gmbh Today - Breaking & Trending Today
Myr GmbH, a company focused on developing therapies for the treatment of chronic hepatitis delta virus (HDV), the most severe form of viral hepatitis. The acquisition brings Myr’s chronic HDV treatment Hepcludex (bulevirtide) under its umbrella. Hepcludex was conditionally approved by the European Medicines Agency (EMA) for the treatment of chronic HDV infection in adults with compensated liver disease in July. Hepcludex is an entry inhibitor that binds to NTCP, an essential HBV and HDV receptor on hepatocytes. It blocks the ability of HDV to enter hepatocytes. Hepcludex is currently the only such medicine approved by the EMA for HDV, the most severe form of viral hepatitis. HDV occurs as a co-infection in individuals who have hepatitis B virus and can have mortality rates as high as 50% within five years in cirrhotic patients. ....
Gilead Sciences wird MYR GmbH erwerben bionity.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from bionity.com Daily Mail and Mail on Sunday newspapers.